AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01765270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: one 5-mg saxagliptin tablet daily
Study NCT01765270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg placebo tablet daily
Study NCT00459823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7107
Description: E7107 administered by intravenous infusion (as a 2-5 minutes bolus) on days 1, 8 and 15 every 28 days.
Study NCT03244982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescein Na 10% Inj 500mg
Description: Full-dose intravenous Fluorescein Na prior to fluorescein angiography.
Study NCT03244982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Na 10% Inj 500mg
Description: Full-dose intravenous Fluorescein Na prior to fluorescein angiography.
Study NCT03244982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescein Na 10% Inj 250mg
Description: Half-dose intravenous Fluorescein Na prior to fluorescein angiography.
Study NCT03244982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Na 10% Inj 250mg
Description: Half-dose intravenous Fluorescein Na prior to fluorescein angiography.
Study NCT04366596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angioplasty with paclitaxel eluting balloon
Description: The patients will be treated with renal artery angioplasty using paclitaxel eluting balloon
Study NCT04366596 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Angioplasty with plain old balloon
Description: Angioplasty with plain old balloon
Study NCT03821792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO
Study NCT03821792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO
Study NCT03821792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT01609231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: Dalotuzumab will be administered intravenously after the completion of irinotecan infusion at a dose of 10 mg/kg once weekly.
Study NCT01609231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180 mg/m\^2 will be administered intravenously once every two weeks either prior to dalotuzumab (Arm A) or after cetuximab (Arm B). Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
Study NCT01609231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 180 mg/m\^2 will be administered intravenously once every two weeks either prior to dalotuzumab (Arm A) or after cetuximab (Arm B). Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
Study NCT01609231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab will be administered intravenously prior to irinotecan at an initial dose of 400 mg/m\^2 followed by weekly infusions of 250 mg/m\^2. Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
Study NCT02366988 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Biliary Stenting
Description: Endoscopic probe self-expandable metallic covered stent Biliary stent will be left in place for 6 months
Study NCT02366988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment Bilio-enteric anastomosis
Description: Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
Study NCT00471146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: oral administration, starting dose 5 mg twice daily \[BID\] every day until unacceptable toxicity or tumor progression.
Study NCT00471146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
Study NCT00471146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
Study NCT00471146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03422042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short duration of antibiotic
Description: Patient will received intravenous antibiotic until the body temperature is less than 37.8 c fir 72, then antibiotic is discontinued.
Study NCT03422042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment of antibiotic
Description: Patient will received intravenous antibiotic for 7 days, followed by oral antibiotic for 7 days, regardless of the body temperature.
Study NCT04288180 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There will be no intervention in this study. Adults with social anxiety disorder will complete research assessments related to fear and safety learning.
Study NCT01044719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin
Description: Tobramycin 7mg/kg/day OD IV
Study NCT01044719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem 2g TDS IV
Study NCT03272321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Syntocinon nasal spray
Study NCT03272321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray
Study NCT01014312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression Care Management (DCM)
Description: Depression Care Management (DCM) includes: 1. Monitoring the course of the depressive disorder; 2. Contacting the referring primary care physician (PCP) and offering information on the patients' current psychiatric status and medical complaints and the treatment recommended by published pharmacotherapy guidelines; 3. Determining the nature and extent of stressors affecting the patients' clinical status and functioning; 4. Psychoeducation concerning depression and depression treatment, working with the patient to select an appropriate treatment based on informed treatment preferences, and emphasizing treatment adherence; and 5. Supportive psychotherapy.
Study NCT01014312 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care
Description: Primary Care Physicians will be informed by letter from a study psychologist of the participants' depression diagnosis and of suicidal ideation when present. They will have no direct assistance regarding depression treatment, but they will be educated on guideline-based antidepressant treatment recommendations. Moreover, research assistants will use a suicide risk protocol at baseline and at all follow-up assessment periods that mandates immediate contact with PCPs by telephone or beeper in cases with significant risk.
Study NCT00753766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial Intervention
Study NCT01518023 — intervention group
Intervention type: OTHER
Intervention: Interview, questionnaire, updated biochemical tests
Description: Patients will be interviewed and questioned about nutritional status, diet, drugs and diagnosis/clinical course of diabetes. Routine biochemical tests will be searched and if necessary updated.
Study NCT01067066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: Starting dose cycle 1, 90 mg/m2 by vein (IV) on Days 1, 8, 15 (+/- 1 day)
Study NCT06616506 — intervention group
Intervention type: DEVICE
Intervention: newly-invented AI model
Description: Apply newly-invented AI models to assist in determining surgical plans and outcome prediction.
Study NCT01067066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodar (Temozolomide)
Description: Starting dose cycle 1, 85 mg/m\^2 by mouth (PO) daily, Day 1 to 5.
Study NCT02478372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Epidural (PCEA)
Description: Following the operation, 4ml of 0.25% levobupivacaine was administered and the catheter was connected to a PCEA. Self-medication with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes until the following morning (post-operative day one) when it was stopped.
Study NCT02478372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Infiltration Analgesia (LIA)
Description: Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine.
Study NCT02651350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Participants will receive methylprednisolone,48mg/d for the 1st week,32mg/d for the 2nd week,24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal.Participants will also receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA) in the first 12 weeks.The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
Study NCT02651350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Participants will only receive standard treatment,namely,routine liver protection drugs including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72.
Study NCT02651350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Participants will only receive standard treatment,namely,routine liver protection drugs including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72.
Study NCT02643290 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Peak Scoliosis Bracing System
Description: Brace is fit to adult scoliosis patients for 2-4 hours a day and tracked for six months.
Study NCT02620007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: oral Ciprofloxacin 500 mg bis in die (bid) for 12 weeks
Study NCT03275337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: tDCS is a non-invasive form of neuromodulation in which direct current is administered placed over a brain region of interest to induce physiological changes such as inhibition or excitation over that region.
Study NCT03275337 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: tDCS is a non-invasive form of neuromodulation in which direct current is administered placed over a brain region of interest to induce physiological changes such as inhibition or excitation over that region.
Study NCT02620007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: oral Rifaximin 800 mg bid for 12 weeks
Study NCT02620007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciprofloxacin Placebo
Description: a placebo of Ciprofloxacin bid for 12 weeks
Study NCT02620007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rifaximin Placebo
Description: a placebo of Rifaximin bid for 12 weeks
Study NCT04300439 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: knee total arthroplasty with two types of ancillaries
Description: -For the Arm A, the surgical procedure of knee total arthroplasty will be done with metallic reusable ancillary.~For the Arm B, the surgical procedure of knee total arthroplasty will be done with Efficiency single use ancillary.
Study NCT04300439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: knee total arthroplasty with two types of ancillaries
Description: -For the Arm A, the surgical procedure of knee total arthroplasty will be done with metallic reusable ancillary.~For the Arm B, the surgical procedure of knee total arthroplasty will be done with Efficiency single use ancillary.
Study NCT02770833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fish and carbohydrats with low or high GI
Study NCT02770833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Veal and carbohydrats with low or high GI
Study NCT01649388 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FCR001
Description: Enriched hematopoietic stem cell infusion
Study NCT01262573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closure of vaginal cuff
Description: Closure of the vaginal cuff
Study NCT01262573 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of vaginal cuff
Description: Closure of the vaginal cuff
Study NCT02380001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol
Description: White round pill containing 25mg of Dexketoprofen will be administered either prior/after to third molar surgery.
Study NCT02380001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preoperative control
Description: white round pill containing 25mg of placebo will be administered prior/after to third molar surgery. The placebo pill is identical to active dexketoprofen, in size and color
Study NCT02315573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wrist block anesthesia
Description: The carpal tunnel release surgery will be performed under wrist block anesthesia. Group 1 will have the wrist block performed with Lidocaine and epinephrine, while Group 2 with Bupivacaine and epinephrine.
Study NCT02350569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally
Study NCT00857428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxymorphone
Description: Tablets
Study NCT00857428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymorphone
Description: 40 mg tablets
Study NCT03800173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: galidesivir
Description: galidesivir IV infusion
Study NCT03800173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo IV infusion
Study NCT04193358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FERTILIS HOMME®
Description: L-carnitine 220 mg, Zinc 20 mg, Selenium 0.03 mg, L-arginine 125 mg, L-glutathione 40 mg, Folic acid (vitamin B-9) 0.4 mg, Coenzyme Q10 7.5 mg, and Vitamin E 60 mg
Study NCT04193358 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Sugar pills
Study NCT03178331 — intervention group
Intervention type: OTHER
Intervention: Study questionnaires
Description: filled by parents, school nurse and teacher
Study NCT02368704 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT04151173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic aspiration/electrocoagulation
Description: laparoscopic aspiration/electrocoagulation of ovarian endometrioma
Study NCT04151173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cystectomy
Description: laparoscopic cystectomy of ovarian endometrioma
Study NCT00331422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin dose (milligrams (mg)) - Target Area Under the Curve (AUC) 6 x (Glomerular Filtration Rate+25) - Calvert Formula, given intravenously (IV) for 30 minutes.
Study NCT00331422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel dose = 175 milligrams per meter squared (mg/m2) over 3 hours.
Study NCT00331422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cytoreductive surgery
Description: Surgery - tumor specimen collected for extreme drug resistant assay (EDR) and A1 assays for analysis
Study NCT02805972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: 4 mg / 0.1 ml
Study NCT02805972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.1 ml
Study NCT00496509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (Zactima) 100mg
Study NCT00496509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)
Study NCT00496509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biomarker Draws
Study NCT00496509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (Zactima) 300mg
Study NCT00412997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study NCT01384942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning-Based Bereavement Group
Description: A 12 week bereavement counselling group with tasks and themes that focus on re-constructing meaning following death.
Study NCT01384942 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Bereavement Group
Description: An 8 week traditional bereavement group that follows a more conventional approach to grief support.
Study NCT04126018 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI with strain measurement
Description: CMR measurements of left and right ventricular systolic function strain and myocardial fibrosis
Study NCT04126018 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Doppler, PISA, VCA, volumetric method as performed during echocardiography
Study NCT06702839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BETY (Cognitive Exercise Therapy Approach )
Description: Individuals with rheumatism were included in BETY sessions after the first session, which included functional gain with function-focused trunk stabilization exercises for their complaints and chronic pain management training based on neuroscience. BETY sessions included function-focused trunk stabilization exercises, chronic pain management, mood information management (dance therapy - authentic movement) as innovative. Individuals were included in a separate session of sexual information management and sleep education.~3 days a week for 3 months
Study NCT06702839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise program
Description: Exercises have been shown and a brochure has been given The individuals in this group were mostly individuals from out of town who were given home exercise recommendations directed by a rheumatologist.
Study NCT00189007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol sodium
Description: Allopurinol sodium 500 mg / 50 mL, intravenously, single dose
Study NCT00189007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: Mannitol 500 mg/50 mL water for injection, intravenously, single dose
Study NCT00252486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flax oil
Description: Flax oil and olive oil placebo were analyzed for quality and purity; sufficient bioactivity was confirmed for the flax oil independently at the University of Massachusetts mid-way through the study. Each capsule of omega -3 fatty acid concentrate contained 550 mg of α-linolenic acid (α-LNA) from flax seed oil.A stepped but flexible dose-titration schedule was carried out with doses increased by 1-2 grams at each visit as tolerated, to an attempted total dose of 6 capsules twice per day, as requested by the FDA (up to 6.6 grams of daily α-linolenic acid).
Study NCT03694574 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: instruction to suppress
Description: It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, try not to think of the situation that makes you angry, mad or irritated. Please try as much as you cannot to think about the situation, don't think about how you feel or what had happened, and try to suppress your emotions and not to feel them. It's very important to try as much as you cannot to think about the situation that makes you angry, mad or irritated. (Szasz, Szentagothai, \& Hoffmann, 2011)
Study NCT03694574 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: instruction to reappraise
Description: It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, please try to tell yourself that or would be preferable that the others are nice and/or fair to you, but if they are not, it does not mean that you or they are worthless human beings. It would be preferable that the others be nice and/or fair to you but if they are not, remember that it is only (very) bad), not catastrophic (the worst thing that could happen to you). It would be preferable that others are nice and/or fair to you, but if they are not, you can tolerate it, and go on enjoying life, even if it's more difficult at the beginning. (Szasz et al., 2011)
Study NCT03694574 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: control
Description: No instruction
Study NCT03405896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Turning
Description: start to walk with normal speed, and then turn to approach the terminal under different angle.
Study NCT03239600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2618960 2 mg/kg
Description: GSK2618960 solution for injection, 100mg/mL is clear to opalescent, colorless to yellow or pale brown liquid.